Small clinical trials: are they all bad?

Area of Science:

• Clinical Trials Methodology
• Biostatistics
• Public Health Research

Background:

• Randomized controlled trials (RCTs) are a cornerstone of medical evidence generation, particularly for diseases with significant public health impact.
• Historically, statisticians have advocated for large sample sizes in RCTs to ensure statistical power and reliable results.
• However, the practicalities of clinical research, especially in less common conditions or specific patient subgroups, often make achieving large sample sizes unfeasible.

Purpose of the Study:

• To critically evaluate the emphasis on sample size in clinical trials.
• To discuss the limitations and potential counterproductivity of solely focusing on large sample sizes.
• To explore alternative considerations in trial design and interpretation beyond mere sample size.

Main Methods:

• Review of existing literature and statistical principles regarding clinical trial design.
• Discussion of case examples where large sample sizes were impractical or detrimental.
• Exploration of the role of hypothesis testing, replication, and statistician involvement in trial design.

Main Results:

• Large sample sizes, while beneficial for common diseases, can be unrealistic and counterproductive in certain clinical trial contexts.
• Overemphasis on sample size may overshadow other critical aspects of trial design and execution.
• Alternative approaches to trial design and interpretation are necessary when large sample sizes are not feasible.

Conclusions:

• The traditional emphasis on large sample sizes in randomized controlled trials needs re-evaluation for broader applicability in clinical research.
• Factors beyond sample size, such as trial replication and the statistician's role, are crucial for generating robust scientific evidence.
• A more pragmatic approach to trial design is required, considering the realities of clinical practice and resource limitations.